Immune interventions to preserve β cell function in type 1 diabetes

Area of Science:

• Immunology
• Endocrinology
• Autoimmune Diseases

Background:

• Type 1 diabetes (T1D) is an autoimmune condition causing pancreatic beta cell destruction.
• Preserving residual beta cells at diagnosis is crucial for better patient outcomes.
• Current treatments for new-onset T1D have not achieved durable remission off therapy.

Purpose of the Study:

• To review immune interventions for new-onset Type 1 diabetes.
• To identify successful therapeutic strategies and future directions.
• To establish immunologic tolerance to beta cells for long-term remission.

Main Methods:

• Review of immune interventions including immunosuppression, immune modulation, antigen-specific, and cellular therapies.
• Analysis of T-cell directed therapies focusing on effector and regulatory T cells.
• Discussion of rational combination therapies for future clinical evaluation.

Main Results:

• No single intervention has yielded durable remission in most patients.
• T-cell directed therapies show the most promise, modulating effector T cells and preserving regulatory T cells.
• Valuable insights into T1D mechanisms and correlates of successful treatment have been gained.

Conclusions:

• Future Type 1 diabetes treatment will likely involve rational combinations of therapies.
• Combination approaches may include effector T-cell modulation, tolerogenic agents, and antigen-specific components.
• The ultimate goal is to restore beta cell function and achieve long-term remission by reestablishing self-tolerance.